Peter Kiener

Peter Kiener has deep experience in drug development with biologics and immunotherapies. He is the former Chief Scientific Officer at Sucampo, prior to which he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates.

Earlier, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held executive roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. He also worked on biologics for Bristol-Myers Squibb prior to his work at MedImmune. Dr. Kiener serves on the Board of Directors of two public companies (Cue Biopharma and Peiris) and has served on scientific advisory boards of several Biotechnology companies.

He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a Doctor of Philosophy in biochemistry from the University of Oxford.